secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0000950170-22-022592
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight Q3 revenue $12.6M (+118% YoY); raises FY22 guidance to $47-48M
----------------------------------------------------------------------

- Q3 2022 revenue of $12.6M, up 118% YoY; LDD installed base reached 343 units (113% YoY increase).
- Sold 6,595 LALs (+234% YoY); gross margin improved to 42.5% vs 23.2% in Q3 2021.
- Raised FY2022 revenue guidance to $47-48M (from $44-46M); gross margin guidance raised to 41-43%.
- Net loss of $(16.8)M or $(0.61)/share vs $(12.7)M or $(0.68)/share in Q3 2021.
- Cash & investments $112.8M; long-term debt $40.0M; operating expense guidance lowered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000095017022022592/0000950170-22-022592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000095017022022592/rxst-20221107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-022592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer